Literature DB >> 11294508

Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.

Z Kossaczka1, S C Szu.   

Abstract

Vibrio cholerae serotype O139 is a new etiologic agent of epidemic cholera. There is no vaccine available against cholera caused by this serotype. V. cholerae O139 is an encapsulated bacterium, and its polysaccharide capsule is an essential virulent factor and likely protective antigen. This study evaluated several synthetic schemes for preparation of conjugates of V. cholerae O139 capsular polysaccharide (CPS) with chicken serum albumin as the carrier protein (CSA) using 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) or 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) as activating agents. Four conjugates described here as representative of many experiments were synthesized in 2 steps: 1) preparation of adipic acid hydrazide derivative of CPS (CPS(AH)) or of CSA (CSA(AH)), and 2) binding of CPS(AH) to CSA or of CPS to CSA(AH). Although all conjugates induced CPS antibodies, the conjugate prepared by EDC-mediated binding of CPS and CSA(AH) (EDC:CPS-CSA(AH)) was statistically significantly less immunogenic than the other three conjugates. Representative sera from mice injected with these three conjugates contained antibodies that mediated the lysis of V. cholerae O139 inoculum. Evaluation of the different synthetic schemes and reaction conditions in relation to the immunogenicity of the resultant conjugates provided the basis for the preparation of a V. cholerae O139 conjugate vaccine with a medically useful carrier protein such as diphtheria toxin mutant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11294508     DOI: 10.1023/a:1007164216202

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  19 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides.

Authors:  D E Shafer; B Toll; R F Schuman; B L Nelson; J J Mond; A Lees
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

3.  Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Authors:  Z Kossaczka; S Bystricky; D A Bryla; J Shiloach; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Colonial opacity variations among the choleragenic vibrios.

Authors:  Richard A Finkelstein; Mary Boesman-Finkelstein; Dilip K Sengupta; William J Page; C Michael Stanley; Thomas E Phillips
Journal:  Microbiology (Reading)       Date:  1997-01       Impact factor: 2.777

5.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 6.  Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.

Authors:  M K Waldor; J J Mekalanos
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

7.  Structure of the capsular polysaccharide of Vibrio cholerae O139 synonym Bengal containing D-galactose 4,6-cyclophosphate.

Authors:  Y A Knirel; L Paredes; P E Jansson; A Weintraub; G Widmalm; M J Albert
Journal:  Eur J Biochem       Date:  1995-09-01

8.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

Review 9.  Epidemiology & molecular biology of Vibrio cholerae O139 Bengal.

Authors:  M J Albert
Journal:  Indian J Med Res       Date:  1996-07       Impact factor: 2.375

10.  Morphological and physical characterization of the capsular layer of Vibrio cholerae O139.

Authors:  Y Meno; M K Waldor; J J Mekalanos; K Amako
Journal:  Arch Microbiol       Date:  1998-10       Impact factor: 2.552

View more
  3 in total

1.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

2.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

3.  Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.

Authors:  Mohammad Kamruzzaman; Meagan Kelly; Pavol Kováč; Peng Xu; Edward T Ryan; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Aklima Akter; Rajib Biswas; M Hasanul Kaisar; Taufiqur R Bhuiyan; Louise C Ivers; Ralph Ternier; Jean-Gregory Jerome; Hélene B Pfister; Xiaowei Lu; Sameh E Soliman; Bart Ruttens; Rina Saksena; Jana Mečárová; Alžbeta Čížová; Firdausi Qadri; Slavomír Bystrický
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.